Alzheon

Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts.[1] The company is developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders.[2]

Alzheon
Public
Traded asNASDAQ: ALZH
IndustryPharmaceutical
Founded2013
HeadquartersFramingham, Massachusetts, United States
Key people
Martin Tolar, MD, PhD (CEO)
Neil Flanzraich (Executive Chairman of the Board of Directors)
Websitewww.alzheon.com

History

Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, who serves as president and CEO of the organization.[3] Alzheon completed a $10 million Series A round of financing in April 2015[4][5] and started the Phase lb bridging clinical program for ALZ-801, which was completed in July 2016.[6][7]

In December 2015, Alzheon appointed Jean-Pierre Garnier, PhD, as Chairman of the Board of Directors.[8]

In January 2017, Alzheon appointed Stanley B. Prusiner, MD, as Chair of its Scientific Advisory Board.[9]

In August 2018, Alzheon appointed former IVAX President Neil Flanzraich, JD, as Vice Chairman of Board of Directors.[10][11]

Pipeline

The company's lead clinical candidate is ALZ-801 an oral small molecule inhibitor of amyloid aggregation and neurotoxicity and an optimized, oral prodrug of the active molecule tramiprosate.[12] Originally developed by a Canadian firm formerly called Neurochem,[13] the drug is expected to target amyloid plaques.[14]

References
  1. Young, Susan (Mar 10, 2016). "Startup Finds Hope in Second Look at "Failed" Alzheimer's Drugs". MIT Technology Review. Retrieved August 24, 2016.
  2. Lash, Alex (11 March 2016). "Failed Alzheimer's Drug To Get Another Shot, If Investors Pony Up". Xconomy. Retrieved 29 April 2017.
  3. Seiffert, Don (March 20, 2015). "Lexington's Alzheon gives its own Alzheimer's news to rival Biogen's". Retrieved August 23, 2016 – via Boston Business Journal.
  4. Fidler, Ben (8 April 2015). "Alzheon Gets $10M to Take Castoff Alzheimer's Drug Into Pivotal Test". Xconomy. Retrieved 29 April 2017.
  5. Billings, Mike (April 8, 2015). "In a Hot Market, Freestyle Capital Raises Larger Fund". The Wall Street Journal. Retrieved August 25, 2016.
  6. "'Gene-dose' effect for Alzheon's ALZ-801, a drug targeting Alzheimer's". The Pharma Letter. Retrieved 29 April 2017.
  7. Fernandes, PhD, Joana (31 March 2017). "Early Alzheimer's Patients with Risk Gene Respond to ALZ-801 in Studies". Alzheimer's News Today. Retrieved 29 April 2017.
  8. Petroni, Susan (16 December 2015). "Alzheon Appoints Former GlaxoSmithKline CEO Jean-Pierre Garnier as Board Chair". Patch Media. Retrieved 17 July 2017.
  9. Begley, Sharon (4 January 2017). "Biotech with big Alzheimer's dreams recruits prion pioneer". Stat News. Retrieved 29 April 2017.
  10. "Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors". www.bloomberg.com. Retrieved 2020-04-09.
  11. "Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors". www.businesswire.com. 2018-08-06. Retrieved 2020-04-09.
  12. "Alzheon's tramiprosate shows meaningful effects in Alzheimer's trial". March 12, 2016. Retrieved August 24, 2016 – via The Pharma Letter.
  13. LaMattina, John. "A Little-Known Drug Company Could Have The Answer For Some Alzheimer's Patients". Forbes. Retrieved 29 April 2017.
  14. Weisman, Robert (July 26, 2016). "Framingham startup plans trials of Alzheimer's treatment". Retrieved August 24, 2015 – via Boston Globe.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.